Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine.
Park
K M
KM
Mayo Clinic, Rochester, Minnesota, USA.
Hay
J E
JE
Lee
S G
SG
Lee
Y J
YJ
Wiesner
R H
RH
Porayko
M K
MK
Krom
R A
RA
D000469:Alkaline Phosphatase / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001851:Bone Diseases, Metabolic / Q000139:chemically induced; D003404:Creatinine / Q000378:metabolism; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000276:immunology*; D016031:Liver Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood; D016559:Tacrolimus / Q000009:adverse effects*; D013997:Time Factors
D007166:Immunosuppressive Agents; D010281:Parathyroid Hormone; D010710:Phosphates; D016572:Cyclosporine; D003404:Creatinine; D000469:Alkaline Phosphatase; D001663:Bilirubin; D016559:Tacrolimus